Meeting
2017 Genitourinary Cancers Symposium
The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
Authors
Daisuke Kajiwara
Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan
Daisuke Kajiwara , Kazuhisa Minamiguchi , Masanao Seki , Hiroya Mizutani , Keisuke Yamamura , Shigeo Okajima , Eiji Sasaki , Teruhiro Utsugi , Yoshikazu Iwasawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 197)
DOI
10.1200/JCO.2017.35.6_suppl.197
Abstract #
197
Poster Bd #
G26
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.
First Author: Vindhya Udhane
Poster
2019 Genitourinary Cancers Symposium
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2015 Genitourinary Cancers Symposium
Effect of lipid nanoparticle siRNA delivery systems on silencing clusterin and progression in enzalutamide resistant prostate cancer in vivo.
First Author: Yoshiaki Yamamoto
Poster
2015 Genitourinary Cancers Symposium
Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer.
First Author: William Douglas Figg